Q-omics provides the consensus-scored TMEM207 profile across patient tissues and cancer cell-line models. TMEM207 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM207 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, TMEM207 RNA expression shows 5,129 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, KIRC, and STAD as cancer lineages where TMEM207 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM207 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM207 survival associations across molecular data types. TMEM207 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM207 RNA expression–survival associations across cancer types. High TMEM207 expression shows unfavorable associations in KIRP, COAD, CHOL and UCEC, but favorable associations in LUSC and UVM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM207 RNA expression.
This table summarizes TMEM207 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM207. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM207 shows lower tumor expression in KIRC, KIRP, KICH and LUSC. The KIRC box plot shows higher TMEM207 RNA expression in normal versus tumor tissue (log2 FC = −4.534, t-test p < 0.001).
This table shows molecular features associated with TMEM207 in patient tissues and cancer cell lines. In patient samples, TMEM207 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM207 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
